Glanbia sales up 10% after starting new joint venture

By Matt Atherton contact

- Last updated on GMT

Glanbia sales increased 9.9% at constant currency in the six months to July 1
Glanbia sales increased 9.9% at constant currency in the six months to July 1
Nutrition firm Glanbia reported a 9.9% rise in group revenue, at constant currency, to £1.67bn (€1.85bn), after starting a new joint venture, and selling 60% of its Dairy Ireland business.

Earnings before interest, tax and amortisation were up 6.6%, in the six months to July 1, Glanbia reported today (August 10).

Growth was driven by its Nutritionals business, and its joint venture – Glanbia Ireland – which encompassed Glanbia Ingredients Ireland and Dairy Ireland, said the group’s md Siobhán Talbot.

“The sale of 60% of Dairy Ireland, and related assets, was completed on July 2,”​ said Talbot. “This business, together with Glanbia Ingredients Ireland, have formed a new joint venture named Glanbia Ireland.

‘Main drivers of growth’

“Glanbia Nutritionals and joint ventures were the main drivers of growth in the first half, and we believe second half earnings progression will also be driven by Glanbia Performance Nutrition where good organic growth is expected for the remainder of the year.”

Glanbia adjusted earnings per share increased 10.1% at constant currency across the six months, to 42p (46.09c). The group’s profit also increased 4.6% to £103.9M (€114.9M).

The Nutritionals business reported a 9% rise in revenue to £580.53M (€642.2M). Growth was driven by a 5.9% price rise, linked to higher dairy markets, Glanbia said.

Glanbia Performance Nutrition was boosted by the firm’s acquisition of Amazing Grass and Body & Fit in February. The business’s revenue increased 5.4% at constant currency to £491.3M (€543.3M).

New innovation centre

The nutrition firm invested £17.3M (€19.1M) across the six months. That included the construction of a new innovation centre in Illinois, US.

Glanbia expected full-year margins to be broadly in line with its first-half, it said. Joint ventures were expected to deliver an improved performance, compared with the previous year, due to improved dairy markets.

Talbot said: “Overall, we reiterate guidance for the full year of pro-forma adjusted earnings per share growth of 7% to 10%, on a constant currency basis.”

Meanwhile, in February, Glanbia reported its seventh consecutive year​ of double-digit earnings growth.

Glanbia half-year results – at a glance

  • Revenue up 9.9% at constant currency to £1.67bn
  • Earnings before interest, tax and amortisation up 6.6% to £134.1M
  • Pro forma adjusted earnings per share up 13.2% to 42p

Related news

Show more

Related product

30544-Fortitech-HeartPart1-Banner-SmartLead-616x347

Strategic Nutrition for Heart Health-Part II

Fortitech® Premixes by DSM | 14-Sep-2017 | Technical / White Paper

Consumers are increasingly shopping for heart healthy products. Identify nutrients that can help differentiate your products and learn how custom nutrient...

comments

Post your comment

We will not publish your email address on the website

These comments have not been moderated. You are encouraged to participate with comments that are relevant to our news stories. You should not post comments that are abusive, threatening, defamatory, misleading or invasive of privacy. For the full terms and conditions for commenting see clause 7 of our Terms and Conditions ‘Participating in Online Communities’. These terms may be updated from time to time, so please read them before posting a comment. Any comment that violates these terms may be removed in its entirety as we do not edit comments. If you wish to complain about a comment please use the "REPORT ABUSE" button or contact the editors.

Follow us

Featured Events

View more

Products

View more